Spain's Sanifit Developing Unique Microcrystal Inhibitor For Calcification In Renal Disease
This article was originally published in Scrip
Spain's fledgling life sciences biotech company Laboratoris Sanifit SL is developing a drug for vascular calcification that has a unique mode of action; it acts to inhibit pathological crystallization processes rather than targeting a receptor, enzyme or protein.
You may also be interested in...
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.
A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.